Focal adhesion kinase inhibition decreases cell viability and induces apoptosis of JAK2 V617F positive cells

Authors

DOI:

https://doi.org/10.1590/

Keywords:

FAK;, Apoptosis;, Myeloproliferative Neoplasms

Abstract

Focal Adhesion Kinase (FAK) protein participates in proliferation, migration, cell survival, and apoptosis process. It has been described as overexpressed in several neoplasms being a promising target for therapy. BCR-ABL negative chronic Myeloproliferative Neoplasms (MPN) are clonal disorders characterized by the excess of proliferation and apoptosis resistance. The identification of the acquired JAK2 V617F mutation in MPN patients allowed a better understanding of pathogenesis. However, there is still no pharmacological treatment that leads all patients to molecular remission, justifying new studies. The present study aimed to evaluate FAK involvement in the viability and apoptosis of HEL and SET-2 cells, both JAK2 V617F positive cell lines. The FAK inhibitor PF 562,271 was used. Cell viability was determined using MTT assay and apoptosis verified by cleaved PARP, cleaved Caspase 3 and Annexin-V/PI staining detection. FAK inhibition significantly reduced HEL and SET-2 cells viability and induced apoptosis. Considering the role of JAK/STAT pathway in MPN, further investigation of FAK participation in the MPN cells proliferation and apoptosis resistance, as well as possible crosstalk between JAK and FAK and downstream pathways may contribute to the knowledge of MPN pathophysiology, the discovery of new molecular targets, and JAK inhibitors resistance mechanisms.

Downloads

Download data is not yet available.

Author Biographies

  • Ana Carolina Menezes Mendonça Valente, Universidade Federal de Juiz de Fora, MG, Brazil
    Performed experiments Analyzed data Wrote the manuscript Critically revised the manuscript.
  • Gustavo Henrique Lima de Farias, Universidade Federal de Juiz de Fora, MG, Brazil
    Performed experiments Critically revised the manuscript.
  • Ana Cristina Ribeiro Bernardo, Universidade Federal de Juiz de Fora, MG, Brazil
    Performed experiments Critically revised the manuscript.
  • Caio Cesar de Souza Alves, Universidade Federal dos Vales do Jequitinhonha e Mucuri. Faculdade de Medicina do Mucuri, Campus Mucuri, Teófilo Otoni, MG, Brazil
    Performed flow cytometry experiments Critically revised the manuscript.
  • Michelle Bueno de Moura Pereira, Universidade Federal de Juiz de Fora, Campus Governador Valadares (UFJF-GV), MG, Brazil
    Conceived the project Designed the experiments Performed experiments Wrote the manuscript Critically revised the manuscript.
  • Raquel Tognon Ribeiro, Universidade Federal de Juiz de Fora. Universidade Federal de Alfenas. Faculdade de Ciências Farmacêuticas, MG, Brazil
    Conceived the project Designed the experiments Performed experiments Wrote the manuscript Critically revised the manuscript.

References

Bousoik E, Montazeri Aliabadi H. “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway. Front Oncol. 2018;8:287. doi: 10.3389/fonc.2018.00287.

» https://doi.org/10.3389/fonc.2018.00287

Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, et al. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017;16(6):1133-44. doi: 10.1158/1535-7163.MCT-16-0719.

» https://doi.org/10.1158/1535-7163.MCT-16-0719

Cho HJ, Park JH, Nam JH, Chang YC, Park B, Hoe HS. Ascochlorin Suppresses MMP-2-Mediated Migration and Invasion by Targeting FAK and JAK-STAT Signaling Cascades. J Cell Biochem. 2018;119(1):300-13. doi: 10.1002/jcb.26179.

» https://doi.org/10.1002/jcb.26179

Chuang HH, Zhen YY, Tsai YC, Chuang CH, Hsiao M, Huang MS, et al. FAK in Cancer: From Mechanisms to Therapeutic Strategies. Int J Mol Sci. 2022;23(3). doi: 10.3390/ijms23031726.

» https://doi.org/10.3390/ijms23031726

El-Sisi MG, Radwan SM, Saeed AM, El-Mesallamy HO. Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival. Mol Cell Biochem. 2021;476(5):1949-63. doi: 10.1007/s11010-020-04030-z.

» https://doi.org/10.1007/s11010-020-04030-z

Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. Epub 20211126. doi: 10.1038/s41392-021-00791-1.

» https://doi.org/10.1038/s41392-021-00791-1

Kessler BE, Sharma V, Zhou Q, Jing X, Pike LA, Kerege AA, et al. FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes. Mol Cancer Res. 2016;14(9):869-82. doi: 10.1158/1541-7786.MCR-16-0007.

» https://doi.org/10.1158/1541-7786.MCR-16-0007

Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008;29(1):9-22. doi: 10.1016/j.molcel.2007.11.031.

» https://doi.org/10.1016/j.molcel.2007.11.031

Lu J, Sun Y, Nombela-Arrieta C, Du KP, Park SY, Chai L, et al. Fak depletion in both hematopoietic and nonhematopoietic niche cells leads to hematopoietic stem cell expansion. Exp Hematol. 2012;40(4):307-17.e3. doi: 10.1016/j.exphem.2011.11.010.

» https://doi.org/10.1016/j.exphem.2011.11.010

Maia V, Ortiz-Rivero S, Sanz M, Gutierrez-Berzal J, Alvarez-Fernández I, Gutierrez-Herrero S, et al. C3G forms complexes with Bcr-Abl and p38α MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion. Cell Commun Signal. 2013;11(1):9. doi: 10.1186/1478-811X-11-9.

» https://doi.org/10.1186/1478-811X-11-9

Ritz C, Baty F, Streibig JC, Gerhard D. Dose-Response Analysis Using R. PLoS One. 2015;10(12):e0146021. doi: 10.1371/journal.pone.0146021.

» https://doi.org/10.1371/journal.pone.0146021

Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-5. doi: 10.1038/nmeth.2089.

» https://doi.org/10.1038/nmeth.2089

Slack-Davis JK, Hershey ED, Theodorescu D, Frierson HF, Parsons JT. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Ther. 2009;8(8):2470-7. doi: 10.1158/1535-7163.MCT-09-0262.

» https://doi.org/10.1158/1535-7163.MCT-09-0262

Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem. 2000;275(21):16309-15. doi: 10.1074/jbc.275.21.16309.

» https://doi.org/10.1074/jbc.275.21.16309

Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14(9):598-610. doi: 10.1038/nrc3792.

» https://doi.org/10.1038/nrc3792

Tavares RS, Nonino A, Pagnano KBB, Nascimento ACKVD, Conchon M, Fogliatto LM et al. Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019. Hematology, transfusion and cell therapy. 2019;41 Suppl 1(Suppl 1). doi: 10.1016/j.htct.2019.03.001.

» https://doi.org/10.1016/j.htct.2019.03.001

Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145-62. doi: 10.1002/ajh.26050.

» https://doi.org/10.1002/ajh.26050

The Jamovi Project (2023). Jamovi (Version 2.3) [Computer Software]. Retrieved from https://www.jamovi.org

» https://www.jamovi.org

Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6). doi: 10.1182/blood-2016-10-695940.

» https://doi.org/10.1182/blood-2016-10-695940

Wang X, Mak PY, Mu H, Tao W, Rao A, Visweswaran R, et al. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Mol Cancer Ther. 2020;19(8):1636-48. doi: 10.1158/1535-7163.MCT-19-0841.

» https://doi.org/10.1158/1535-7163.MCT-19-0841

Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis. 2013;30(5):579-94. doi: 10.1007/s10585-012-9562-5.

» https://doi.org/10.1007/s10585-012-9562-5

Downloads

Published

2023-08-28

Issue

Vol. 59 (2023)

Section

Article

License

Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.

The on-line journal has open and free access.

How to Cite

Focal adhesion kinase inhibition decreases cell viability and induces apoptosis of JAK2 V617F positive cells. (2023). Brazilian Journal of Pharmaceutical Sciences, 59, e23075. https://doi.org/10.1590/